Cinacalcet Hydrochloride Therapy for Secondary Hyperparathyroidism in Hemodialysis Patients
Authors:
- El‐ ShafeyESEl‐ Shafey
- Eid MEMEid M
- Ali E AlsahowAAAli E Alsahow
- Khalid AlsaranKAKhalid Alsaran
- Alaa A SabryASAlaa A Sabry
- Mohamed AtiaMAMohamed Atia
- 23 November 2011
- journal article
- research article
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 15 (6) , 547-555
Abstract
This study compared the efficacy of a cinacalcet‐based regimen with unrestricted conventional therapy (vitamin D and phosphate binders) for achieving Kidney Disease Outcome Quality Initiative (K/DOQI) targets for dialysis patients. In this multicenter, prospective study, hemodialysis patients with poorly controlled secondary hyperparathyroidism (SHPT) were randomized to receive a cinacalcet‐based regimen (n = 55) or a conventional therapy (n = 27). Doses of cinacalcet, vitamin D sterols, and phosphate binders were adjusted during a 12‐week dose‐titration phase to achieve intact parathyroid hormone (iPTH) levels ≤ 31.8 pmol/L. The primary end point was the percentage of patients with values in this range during a 24‐week efficacy‐assessment phase. The clinical response to 36‐week cinacalcet treatment was evaluated. A dual energy X‐ray absorptiometry was performed before and after 36 weeks of cinacalcet therapy. Fifty‐eight percent of the cinacalcet group reached the primary end point, as compared with 19% of the conventional therapy group (P = 0.001). A higher percentage of patients receiving the cinacalcet‐based regimen versus conventional therapy achieved the targets for calcium, phosphorus and Ca × P. Achievement of targets was greatest in patients with less severe disease (intact PTH range, 31.8 to 53 pmol/L). Cinacalcet therapy increased proximal femur bone mineral density (BMD), but did not affect the lumbar spine. Itching intensity decreased significantly. Cinacalcet based treatment facilitates achievement of the K/DOQI targets for iPTH and bone mineral metabolism compared with conventional therapy in hemodialysis patients. Suppression of iPTH with cinacalcet reverses bone loss in the proximal femur. Cinacalcet alleviated itching.Keywords
This publication has 21 references indexed in Scilit:
- Cinacalcet – Clinical and Laboratory Effectiveness, Concomitant Treatment Patterns and Treatment Cost: Could We Do Better and How?Kidney and Blood Pressure Research, 2010
- The OPTIMA StudyClinical Journal of the American Society of Nephrology, 2008
- Cinacalcet HCl (Sensipar/ Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidismClinical Nephrology, 2007
- Cinacalcet Hydrochloride (Sensipar) in Hemodialysis Patients on Active Vitamin D Derivatives with Controlled PTH and Elevated Calcium × PhosphateClinical Journal of the American Society of Nephrology, 2006
- Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidismNephrology Dialysis Transplantation, 2005
- Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns StudyKidney International, 2005
- Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidismKidney International, 2005
- Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)American Journal of Kidney Diseases, 2004
- Mineral Metabolism, Mortality, and Morbidity in Maintenance HemodialysisJournal of the American Society of Nephrology, 2004
- Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis populationKidney International, 2003